Meeting
2013 ASCO Annual Meeting
A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC?
Authors
Lina Pugliano
Jules Bordet Institute, Breast International Group, Brussels, Belgium
Lina Pugliano , Dimitrios Zardavas , Marianne Paesmans , Ivana Sestak , Richard D. Gelber , Jack M. Cuzick , Mitchell Dowsett , Ahmad Awada , Martine J. Piccart-Gebhart , Evandro De Azambuja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 575)
DOI
10.1200/jco.2013.31.15_suppl.575
Abstract #
575
Poster Bd #
5F
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.
First Author: Hao Liao
Poster
2012 ASCO Annual Meeting
Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17.
First Author: Pedro Emanuel Rubini Liedke
Poster
2011 ASCO Annual Meeting
Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.
First Author: G. Lunardi
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel